HIF1A and hepatocellular carcinoma: demonstrated that Simvastatin could suppress the HIF-1α/PPAR-γ/PKM2 signaling pathway by inhibiting PKM2-mediated glycolysis, thereby promoting and lowering apoptosis and proliferation of HCC cells, respectively.